Asterisk (*) and section sign () indicate significant variations (*p?
Asterisk (*) and section sign () indicate significant variations (*p?
have received research grant support from NIH National Institute of Allergy and Infectious Diseases (NIAID), ancillary mechanistic grant associated with Grant 3U01AI063594-17S1
have received research grant support from NIH National Institute of Allergy and Infectious Diseases (NIAID), ancillary mechanistic grant associated with Grant 3U01AI063594-17S1. by IgG2 (36%). Comparatively, there was a higher prevalence of IgA (85% versus 14%, = 0.0001) and IgM (87%, versus 36%, = 0.001) in the antiCSARS-CoV-2 antibody profile, when compared to DSAs, respectively. AntiCSARS-CoV-2 antibody profile was characterized by increased prevalence of IgM and IgA, when compared to DSAs. The median calculated panel reactive antibody before COVID-19 diagnosis (24%) tended to decrease after COVID-19 diagnosis (10%) but it was not statistically significant (= 0.1). Conclusions. Anti-HLA antibody strength and calculated panel reactive antibody in kidney transplant recipients after COVID-19 do not significantly increase after contamination. Although the IgG isotype was the dominant form in both HLA and SARS-CoV-2 antigens, the alloimmune response had a low IgA pattern, whereas antiCSARS-CoV-2 antibodies were high IgA/IgM. Open in a separate window…